Antibody-drug conjugates (ADCs) have long been hailed as the magic bullets of oncology, combining the targeting specificity of antibodies with the potency of cytotoxic agents. Despite their clinical success, challenges such as tumor heterogeneity, acquired resistance, and limited therapeutic windows continue to influence treatment outcomes.

To overcome these challenges without compromising safety, Dual-Payload ADCs and Peptide-Drug Conjugates (PDCs) are emerging, offering a single-molecule alternative to complex combination therapies. By integrating two therapeutic agents into a single targeted molecule, these platforms aim to expand antitumor activity while maintaining the advantages of selective drug delivery.

What Are Dual-Payload ADCs?

Traditional ADCs consist of three key components: an antibody, a linker, and a single payload. After binding to a tumor-associated antigen, the ADC is internalized by the cancer cell, where the payload is released to exert its therapeutic effect.

Dual-payload ADCs build on this concept by incorporating two payloads within the same antibody construct. These payloads may possess distinct mechanisms of action or complementary biological activities, enabling a single ADC to address multiple pathways involved in tumor growth and survival.

Recent advances in linker chemistry have further accelerated development in this area. Dual-payload linkers allow two payloads to be incorporated through a streamlined conjugation strategy, simplifying manufacturing while improving control over payload distribution and product homogeneity.

Advantages of Dual-Payload ADCs

Overcoming Resistance & Heterogeneity: By simultaneously disrupting parallel biological pathways (e.g., microtubule disruption + DNA damage) or targeting distinct nodes of the same pathway, these molecules prevent tumor sub-populations from escaping, significantly outperforming single-payload combinations in multi-drug resistant models.

Remodeling the Tumor Microenvironment (TME): Dual-payload designs allow one toxin to eliminate tumor cells directly while the other (such as an immunomodulator or RNAi molecule) targets tumor-associated fibroblasts (CAFs) or immunosuppressive cells. This sequential or synchronized release amplifies the bystander effect, eradicating surrounding antigen-negative tumor cells.

Optimizing the Therapeutic Window: Compared to co-administering two separate single-payload ADCs, a single dual-payload entity eliminates target competition and pharmacokinetic (PK) mismatches, reducing systemic toxicity and patient burden.

Global Pipelines of Dual-Payload ADCs/PDCs

The dual-payload landscape has progressed from its initial concept in 2017 (targeting CD30 with an MMAE+MMAF combination) to a highly competitive arena featuring over 20 global biopharma players.

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, dual-payload platforms became a dominant highlight. Dozens of candidates presented preclinical data demonstrating therapeutic efficacy superior to mono-ADC combinations.

Table 1. Global Dual-Payload Conjugate Pipelines

While dual-payload ADCs currently lead in clinical progress, dual-payload PDCs are rapidly catching up. Utilizing small, highly flexible peptides, PDCs offer superior tumor penetration and hyper-precise, TME-specific sequential payload activation.

Linker Technology & Future Outlook

The success of a dual-payload conjugate relies heavily on linker architecture. Integrating cleavable dipeptides (e.g., Val-Cit) with self-immolative PABC spacers is critical to maintaining high circulatory stability while ensuring efficient, site-specific payload release upon lysosomal enzyme or TME protease (like FAP) cleavage.

As a worldwide leading manufacturer and supplier of PEG linkers and biochemical solutions, Huateng Pharma is fully committed to supporting this wave of innovation. Beyond our PEG catalog, we offer custom PEG synthesis solutions to provide the flexibility, precision, and technical expertise required to streamline your development workflows from discovery to advanced clinical stages.

References:

1. Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.
   

2. Callio Therapeutics. Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221. GlobeNewswire. 2026-03-24.
   

3. A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance.
   

4. Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm Sin B. 2023 Feb;13(2):498-516. doi: 10.1016/j.apsb.2022.07.020. Epub 2022 Aug 3. PMID: 36873165; PMCID: PMC9978859.